nad+ and semaglutide together Peptide Therapy NAD+ and Tirzepatide Together: Safety

Wegovy may offer additional benefits, such as reducing cardiovascular risk, which is an FDA-approved use

In a large retrospective cohort study including over 1.6 million patients with Type 2 Diabetes, with no prior diagnosis of obesity associated cancers, a significantly reduced risk in 10 out of 13 obesity associated cancers was reported with the use of GLP-1 agonists, including esophageal, colorectal, endometrial, gallbladder, kidney, liver, ovarian, pancreatic cancer, meningioma, and multiple myeloma 17

Reynolds AN, Akerman AP, Mann J

P., Laursen, P

We believe plan sponsors should start preparing now for increased demand and develop a program approach that balances providing access with maintaining benefit affordability.

Hit 10mg by week seven